ICRF 192
ICRF 192 is a weak DNA topoisomerase II (DNA topoisomerase II) inhibitor with an IC50 of 91 μM. ICRF 192 forms an iron-chelating derivative via ring-opening hydrolysis, which can displace Fe3+ from the Fe3+-doxorubicin complex. ICRF 192 is used for studies on the structure-activity relationship of bisdioxopiperazines and the cardiotoxicity of anthracycline drugs.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 58893-33-7
- 分子式: C12H18N4O4
- 分子量:282.30
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Topoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
|
Topoisomerase II 91 μM (IC50) |
IC50 192 exhibits essentially no inhibitory activity against the growth of Chinese hamster ovary (CHO) cells, which is consistent with its weak inhibitory activity against DNA topoisomerase II[1].
ICRF 192 (concentration range; 48 h) inhibits the growth of Chinese hamster ovary (CHO) AA8 cells with an IC50 of 340 μM[3].
ICRF 192 (over a range of concentrations) inhibits the growth of mouse L cells, with an IC50 of 720 μM[3].
ICRF 192 (0-100 μM; 30 min) inhibits the catalytic decatenation activity of DNA topoisomerase II derived from human leukemia K562 cells, with an IC50 of 91 μM[3].
ICRF 192 (20-200 μM; approximately 2-3 h) enters BHK-21S cells via simple diffusion, and the intracellular concentration reaches a level close to that of the extracellular medium[2].
ICRF 192 (100 μM; 24 h) does not undergo significant metabolism in BHK-21S cells, and the radioactivity associated with cellular DNA and RNA originates from incorporation via the one-carbon metabolic pathway, rather than covalent binding of the drug[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SHR, Aoki-Okamoto strain (adult male, 200-250 g, doxorubicin-induced chronic cardiotoxicity and nephrotoxicity model)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once weekly; 12 weeks; 30 minutes prior to doxorubicin
-
Result:Caused an average body weight decrease of 13 g in surviving rats.
Did not significantly reduce doxorubicin-induced myocardial lesions.
Among 10 evaluated animals, 1 animal had a myocardial lesion score of 2.0, 4 animals had a score of 2.5 and 5 animals had a score of 3.0.
Did not significantly reduce doxorubicin-induced renal lesions. Among 11 evaluated animals, 1 animal had a renal lesion score of 1, 4 animals had a score of 2 and 6 animals had a score of 3.
Resulted in 6 deaths among 11 animals before study completion.
化学情報
-
CAS 番号 58893-33-7
-
分子量 282.30
-
分子式 C12H18N4O4
-
SMILES
O=C1NC(CN(CC(CC)N2CC(NC(C2)=O)=O)C1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Herman EH, et al. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer chemotherapy and pharmacology. 1997;40(5):400-408. [Content Brief]
[2]. Dawson KM. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol. 1975 Dec 15;24(24):2249-2253. [Content Brief]
[3]. Hasinoff BB, et al. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochemical pharmacology. 1995 Sep 28;50(7):953-958. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
ICRF 192 関連分類
HY-183524 関連分類
Powered by Bioz